Back to search

Article

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

2022-03-01

Abstract excerpt

<h4>Background: </h4> Pomalidomide in combination with dexamethasone has demonstrated positive results in patients with relapsed or refractory multiple myeloma (RRMM), but no data are available in China. We conducted a multicenter, single-arm trial to examine the efficacy and safety of a generic pomalidomide in combination with low-dose dexamethasone in Chinese RRMM patients. <h4>Methods: </h4>: Adult (≥18 years o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c93c9c23-2882-5885-8691-1c7b0f83cba4
DOI
10.21203/rs.3.rs-1178265/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trialDOI 10.21203/rs.3.rs-1178265/v1
Multi-omics investigation of the resistance mechanisms of Pomalidomide in Multiple MyelomaSemantic proximity
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsSemantic proximity
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaSemantic proximity
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Semantic proximity
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myelomaSemantic proximity
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.Semantic proximity
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity
Pattern of Use and Efficacy of Daratumumab-based Therapy in Patients With Multiple Myeloma in a Real-world Setting: a Single Institution ExperienceSemantic proximity
Treatment outcome of newly diagnosed multiple myeloma patients: A retrospective analysis in a resource-limited settingSemantic proximity
Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myelomaSemantic proximity
Downregulation of Chemokine CCL20&nbsp;Involved in Myeloma Cells Resistant to Elotuzumab and LenalidomideSemantic proximity
Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity
Select a neighboring publication to make it the new centre.